洛拉替尼在新型 KIF5B-ALK 融合癌激酶肺腺癌治疗策略中的 应用 1 例
摘要
关键词
全文:
PDF参考
[1]Hastings PJ，Lupski JR，Rosenberg SM，Ira G. Mechanisms of change in gene copy number. Nat Rev Genet. 2009 Aug；
10(8）：551-64.
[2]Kengo Takeuchi，Young Lim Choi，Yuki Togashi，Manabu Soda，Satoko Hatano，Kentaro Inamura，Shuji Takada，Toshihi
de Ueno，Yoshihiro Yamashita，Yukitoshi Satoh，Sakae Okumura，Ken Nakagawa，Yuichi Ishikawa，Hiroyuki Mano；KIF5B
-ALK，a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Ca
ncer. Clin Cancer Res 1 May 2009；15(9）：3143–3149.
[3]Xiang，Y.；Zhang，S.；Fang，X.；Jiang，Y.；Fang，T.；Liu，J.；Lu，K. Therapeutic Advances of Rare ALK Fusions in
Non-Small Cell Lung Cancer. Curr. Oncol. 2022，29，7816-7831.[4]Wong DW，Leung EL，Wong SK，Tin VP，Sihoe AD，Cheng LC，Au JS，Chung LP，Wong MP. A novel KIF5B-ALK
variant in nonsmall cell lung cancer. Cancer. 2011 Jun 15；117(12）：2709-18.
[5]Akamine T，Toyokawa G，Tagawa T，Seto T. Spotlight on lorlatinib and its potential in the treatment of NSCLC：the evid
ence to date. Onco Targets Ther. 2018 Aug 22；11：5093-5101.
[6]Felip E，Shaw AT，Bearz A，Camidge DR，Solomon BJ，Bauman JR，Bauer TM，Peters S，Toffalorio F，Abbattista A，
Thurm H，Peltz G，Wiltshire R，Besse B. Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive no
n-small-cell lung cancer previously treated with second-generation ALK TKIs. Ann Oncol. 2021 May；32(5）：620-630.
[7]Shaw AT，Solomon BJ，Chiari R，Riely GJ，Besse B，Soo RA，Kao S，Lin CC，Bauer TM，Clancy JS，Thurm H，Mar
tini JF，Peltz G，Abbattista A，Li S，Ou SI. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer：a multicentr
e，open-label，single-arm，phase 1-2 trial. Lancet Oncol. 2019 Dec；20(12）：1691-1701.
[8]Dagogo-Jack I，Rooney M，Lin JJ，Nagy RJ，Yeap BY，Hubbeling H，Chin E，Ackil J，Farago AF，Hata AN，Lenner
z JK，Gainor JF，Lanman RB，Shaw AT. Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diver
sity. Clin Cancer Res. 2019 Nov 15；25(22）：6662-667
(0 摘要 Views, 0 PDF Downloads)
Refbacks
- 当前没有refback。